ifcg for first-line treatment of ighv-mutated cll
Published 4 years ago • 350 plays • Length 2:32Download video MP4
Download video MP3
Similar videos
-
1:43
long-term outcomes of the ifcg regimen for firstline treatment of patients with ighv-mutated cll
-
1:46
ifcg proves promising for ighv-mutated cll
-
1:35
ifcg: a promising new regimen for treating ighv-mutated cll
-
3:13
selection for time-limited & continuous therapy in cll
-
1:11
the prognostic value of ighv mutational status with continuous vs time-limited therapy in cll
-
2:08
the differences in outcomes and treatment in cll patients with mutated and unmutated ighv
-
1:14
cll: ighv mutational status
-
1:15
optimizing initial therapy of cll
-
2:14
novel approaches to first line cll treatment
-
0:53
clinical significance of ig gene mutations in cll
-
17:52
diagnosis and initial treatment of cll
-
3:15
should standard chemotherapy regimens be altered in favor of small molecules? ifcg for frontline cll
-
1:17
optimizing initial therapy in cll: time-limited, all-oral approaches
-
2:36
treatment approaches to cll with high-risk molecular features
-
1:36
selecting the best treatment option in cll
-
2:51
key btk inhibitor trials for the initial treatment of cll
-
1:28
the future of cll treatment
-
1:18
the use of genomics to help select treatment in cll
-
2:06
effects of dose adjustment of first-line ibrutinib on real-world dosing patterns and outcomes in cll